Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
28 hedge funds and large institutions have $6.17M invested in Biolase, Inc. in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 13 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
10% less capital invested
Capital invested by funds: $6.85M → $6.17M (-$680K)
26% less funds holding
Funds holding: 38 → 28 (-10)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$31.4K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$19.4K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$14.8K |
| 4 |
Jane Street
New York
|
+$11.1K |
| 5 |
Renaissance Technologies
New York
|
+$9.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$31K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$27K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$23K |
| 4 |
HF
HRT Financial
New York
|
-$14.8K |
| 5 |
VCM
Virtue Capital Management
Brentwood,
Tennessee
|
-$14K |
BIOL Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2022, worth a combined $6.17M — down 9.9% from $6.85M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BIOL and 3 opened new positions — a net loss of 10 holders — while 3 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, adding an estimated $31.4K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $31K sold.
- 28 institutional investors held Biolase, Inc. (BIOL) as of Q1 2022, down from 38 in Q4 2021.
- Funds reported $6.17M of Biolase, Inc. stock for Q1 2022, down 9.9% quarter-over-quarter.
- 3 funds opened new Biolase, Inc. positions in Q1 2022 and 13 closed out, a net change of -10 holders.
- The largest Biolase, Inc. buyer in Q1 2022 was Millennium Management, an estimated $31.4K added.
- The largest Biolase, Inc. seller in Q1 2022 was Acadian Asset Management, an estimated $31K sold.
Based on aggregated 13F filings for Q1 2022.